These results are certainly welcome and support the fundamental...

These results are certainly welcome and support the fundamental analysis that most of us have backed with hard coin.
They are also a relief and if it didn't work, many board members would be questioning themselves.
Vince has played with the big boys, he didn't come here to wreck his career, so I was quietly confident these results would be good.

These are the new boxes ticked since the SP cap raise.
-It nows paves the way forward for both 1702 and 1503 to go to Phase 3 trials with a lot of confidence.
- At 10% concentration of synthetic CBD, safety isn't an issue and it works really well.
-All of the shorts are now covered in one hit, which seemed to coincide with Credit Suisse leaving as a Prime Broker. It is always a good thing to see no shorts. I am not against shorting by any means because it adds to the market particpation and is a good hedge in some cases. If you are long it also helps with the topside price action when shorters are forced to cover. i.e. they help create "blow off tops".

Who wants to pony up now to help us through Phase 3 of BTX1503 and BTX1702? One giant pharma assist for the 2 products or 2 giants? SP is obviously sorted for this.

What other junior biotech listed on the ASX could potentially have 3 products going the Phase3 FDA process at once next year ?